In this video, Prof. Hanny Al-Samkari of Harvard Medical School shares key insights from the VEHIT-2 Phase III randomized trial evaluating ianalumab in early second-line immune thrombocytopenia (ITP). He discusses the study’s novel endpoint of time to treatment failure, the durable efficacy seen at both dosing levels when combined with eltrombopag, and the favorable safety profile observed to date. The conversation also touches on ongoing long-term follow-up and the potential for disease modification in ITP.
